Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Staphaseptic
- Development stage
- Discontinued
- Lead developer
- Tec Laboratories
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Staphaseptic is a topical antiseptic and analgesic gel developed by Tec Laboratories. It contains a combination of benzethonium chloride (a quaternary ammonium antiseptic), lidocaine (a local anesthetic), and essential oils including tea tree and white thyme oil. The product was primarily marketed for the prevention of infection and relief of pain in minor skin injuries such as cuts, scrapes, and burns. Although research indicated bactericidal activity against methicillin-resistant *Staphylococcus aureus* (MRSA), the FDA issued a warning letter in 2011 regarding unapproved claims for MRSA prevention. The product was subsequently rebranded as Tecnu First Aid Gel and has since been discontinued.
- Brand names
- StaphasepticTecnu First Aid Gel
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on Staphaseptic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Staphaseptic.